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Realizing the Potential of Cancer Prevention
— The Role of Implementation Science
Karen M. Emmons, Ph.D., and Graham A. Colditz, M.D., Dr.P.H.
In the past two decades, we and others have
estimated that more than half of cancers could
have been prevented by applying knowledge that
we already have. Tobacco use, inactivity, and
obesity are modifiable causes of cancer,1-3 and
evidence now suggests that vaccination against
the human papillomavirus, the use of aspirin
and selective estrogen-receptor modulators, and
participation in screening programs further reduce the risk of specific cancers.4,5 The effect of
these strategies on cancer-related outcomes in
the general population is significant. A 62% reduction in lung-cancer mortality is associated
with smoking cessation at age 50,6 and environmental and policy strategies are effective at increasing cessation.6-8 A 95% reduction in mortality is associated with screening for cervical
cancer,9 a 100% reduction in mortality is associated with vaccination against the human papillomavirus,10-12 and a 90% reduction in mortality
related to chronic liver disease and liver cancer
is associated with vaccination against hepatitis B
virus.13 There is also benefit for those at high
risk for cancer. Lung-cancer screening is associated with a 20% reduction in mortality among
smokers at high risk, salpingo-oophorectomy
reduces the risk of breast and ovarian cancer
among women with a BRCA1/2 mutation,14,15 and
treatment with selective estrogen receptor modulators reduces the incidence of breast cancer by
50% among women at high risk.16,17 Screening,
diagnosis, and treatment of hepatitis C virus
infection reduces the risk of all-cause mortality
by 50% among those with infection.18 Our ability to prevent cancer has improved significantly.

How Well D o We Use the E vidence
on C ancer Pre vention?

has the longest-standing evidence base. Environmental and policy approaches (e.g,. taxation and
restrictive policies) that reduce the rate of risky
behaviors and that increase access to treatment
are particularly important for tobacco control at
the population level.6-8,26 However, the current
federal excise tax on tobacco, $1.01, is low as
compared with the average of about $3.15 per
pack in high-income countries worldwide. There
is often statistically significant variation among
the states in the implementation of the evidence
base. One example is state tobacco taxes, which
range from 17 cents to $4.35 per pack of cigarettes.27 Raising cigarette excise taxes at the
state and federal levels is viewed as a key strategy in reducing smoking prevalence, yet almost
one third of states have not raised their taxes in
10 years. Long-standing gaps in access to cessation treatment were addressed in the Affordable
Care Act (ACA),28,29 which is now at risk.
Similar gaps in the implementation of the
evidence base can be seen in nearly all known
cancer-prevention strategies. Simply put, as a
nation, we continue to underinvest in primary
prevention and screening and fail to adopt strategies to ensure that all population groups benefit equally from our knowledge of cancer prevention. As a result, cancer morbidity and
mortality are unnecessarily high,30 and these
high rates translate into huge health care costs
and a devastating burden for patients and their
families.31,32 Prevention is much less expensive.
For example, the economic cost of smoking is
estimated at $300 billion a year.33 Every $1 expended on a comprehensive smoking-cessation
program in Massachusetts was associated with a
return on investment of $2.12.34

How C an We Ma ximize the Use

The evidence on cancer prevention has not been
of E xis ting E vidence?
adopted in the United States as effectively as it
might have been (Table 1). Among the strategies If we wish to increase the use of the existing
for the prevention of cancer, smoking cessation evidence on cancer prevention, it is imperative
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Table 1. Prevalence of Factors That Modify the Risk of Cancer in the United States.*

Risk Modifiers

Average National
Prevalence, 2014
and 2015

States with Highest and Lowest Prevalence
Highest

Source

Lowest

percent
Cigarette smoking
Adult

15.1 (2014)

West Virginia, 26.7

Utah, 9.7

Data on national prevalence19 and
statewide prevalence20 are from
the CDC.

Youth

10.8 (2014)

West Virginia, 18.8

Utah, 4.4

All data are from the CDC.21

BMI ≥30†

29.8 (2014)

Louisiana, 36.2

Colorado, 20.2

Data are from the CDC.22

Lack of physical
activity‡

22.1 (2014)

Mississippi, 31.4

Colorado, 16.4

Data are from the CDC.22

Fruit intake (≥2 cups/day)

13.1 (2013)

California, 17.7

Tennessee, 7.5

Data are from Moore and
Thompson.23

Vegetable intake (2.5–3
cups/day

8.9 (2013)

California, 13.0

Mississippi, 5.5

Data are from Moore and
Thompson.23

Screening for colon
cancer§

66.4 (2014)

Massachusetts, 76.5

Wyoming, 56.9

Data are from the CDC.20

Mammography¶

73.0 (2014)

Massachusetts, 82.1

Idaho, 62.5

Data are from the CDC.20

Pap test‖

82.6 (2014)

Massachusetts, 88.0

Idaho, 76.2

Data are from the CDC.20

HPV vaccination**

Girls: 41.9
Boys: 28.1
(2015)

Girls:
Rhode Island, 68.0
Boys:
Rhode Island, 58.1

Girls:
Mississippi, 24.4
Boys:
Tennessee, 16.0

Data are from Reagan-Steiner et al.24

HBV vaccination††

72.4 (2014)

North Dakota, 88.4

Vermont, 48.4

Data are from Hill et al.25

*	CDC denotes Centers for Disease Control and Prevention.
†	BMI denotes body-mass index, calculated as the weight in kilograms divided by the square of the height in meters. Some organizations
now classify obesity as a BMI of 30 or higher.
‡	The lack of physical activity is defined as no leisure-time physical activity among persons 18 years of age or older.
§	The percentages for colon-cancer screening are based on persons between 50 and 75 years of age for whom the screening met the recommendations of the U.S. Preventive Services Task Force.
¶	Data on mammography are from women 40 years of age or older who had a mammogram within the preceding 2 years.
‖	Data on the Papanicolaou (Pap) test are from women 21 to 65 years of age who had a Pap test within the preceding 3 years.
**	These children received at least three vaccinations against the human papillomavirus (HPV).
††	Vaccinations against hepatitis B virus (HBV) were administered from birth through the age of 3 days.

that we conduct more dissemination research
and implementation research focused on cancer
prevention. Dissemination research is the systematic study of processes and factors that lead
to the widespread use of an evidence-based practice.35 Implementation research focuses on understanding the processes and factors that are
associated with the successful integration of
evidence-based practices in a particular setting
(e.g., a primary care clinic or school) and on
evaluating the effects of any adaptations of the
practices that are needed in that setting. Together, these two approaches, supported by strong
and growing methods, can help us bend the
curve on the use of evidence on cancer prevenn engl j med 376;10

tion. Dissemination and implementation research
focused on the strategies needed to enhance
population-level cancer prevention may be particularly productive.26
Environmental and policy initiatives can reach
a large number of people efficiently.6-8 Dissemination and implementation research can help to
elucidate organizational factors that may speed
implementation differentially across settings. For
example, worksite smoking bans and comprehensive smoking-cessation programs have been
effective strategies for reducing smoking among
adults,7 and the organizational characteristics
associated with the adoption of smoking bans
have been identified.36,37 Future opportunities for

nejm.org

March 9, 2017

987

The New England Journal of Medicine
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on March 21, 2017. For personal use only. No other uses without permission.
Copyright © 2017 Massachusetts Medical Society. All rights reserved.

The

n e w e ng l a n d j o u r na l

policy interventions might focus on areas where
there has been resistance to the adoption of
evidence-based strategies, such as states with
low excise taxes or limited implementation of
restrictive smoking policies, as noted above. Environments that provide access to groups with an
elevated prevalence of risk-related behaviors are
another important target. For example, higher
rates of implementation of evidence-based
tobacco-control interventions are needed in settings that provide care to people with mental
health and substance-abuse issues, since the
prevalence of smoking in these two groups is
much greater than that in the general population.38 Only 35% of substance abuse treatment
facilities39 have a smoking ban, only about half
provide any counseling or medication for smoking cessation,40 and psychiatrists deliver cessation counseling to patients who smoke at only
12% of visits.41 Despite the demonstrated efficacy of smoking-cessation treatment in the context of mental health care, only 13 states require
provision of cessation treatment in facilities that
provide treatment for alcohol abuse, drug abuse,
or other conditions related to mental health.42 It
is likely that the facilitators of the adoption of
antismoking policies are different in treatment
centers and the workplace. Dissemination and
implementation research can help to determine
how to increase the use of smoking bans and the
provision of comprehensive treatment in these
settings, as can changes in state and federal
policy that provide protection from exposure to
secondhand smoke and ensure access to cessation treatment.
The setting in which cancer is treated is another important target for increasing the use of
evidence on cancer prevention. The 2014 Surgeon General’s report concludes that there is a
causal relationship between smoking and adverse health outcomes and mortality among
people with cancer and that all-cause mortality
could be lowered in such people by 30 to 40% if
they would stop smoking at the time of diagnosis.7 Reasoning by analogy, a cancer center that
did not use evidence-based chemotherapy protocols would not be competitive for funding from
the National Cancer Institute. Applying the same
expectation for the evidence-based treatment of
behavioral risk factors among people with known
cancer could accelerate the reduction in the risk
of death for the 13 million cancer survivors in
988
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the United States and thereby benefit not only
patients but their families and caregivers. Dissemination and implementation research should
focus on improving our understanding of the
factors at the provider, patient, organizational,
and policy levels that impede the adoption of
evidence-based cancer-prevention strategies.
Increased population-level access to cancer
prevention can also be achieved by focusing research efforts across multiple levels of influence,
often through new and nontraditional partnerships. As the examples above illustrate, there is a
need for both policies that encourage behaviors
related to risk reduction and access to evidencebased treatments. If the ACA is largely repealed,
access to evidence-based treatment will be reduced or eliminated for millions of smokers.
Access to cancer-screening services will also be
reduced. Other avenues of access must be created. The Center for Medicare and Medicaid Services (CMS) could use its innovation awards to
aid the development of new strategies that would
provide access to screening services and to expand the use of evidence-based cancer-prevention strategies, as it has done in helping to reduce the risk of cardiovascular disease. It would
be valuable to determine whether state-level
efforts lead to outcomes that are different from
those supported by CMS investment, whether
CMS resources could be used to advance statelevel efforts to boost the implementation of evidence-based research, and whether partnerships
with parties whose focus is not health care (e.g.,
schools, churches, and government agencies
such as agriculture and housing) could help to
increase use. In collaboration with the National
Institutes of Health and the Centers for Disease
Control and Prevention, targeted research opportunities could be created to maximize the knowledge gained.
Social determinants contribute to disparities in
cancer morbidity and mortality.43 Organizations
that serve communities with limited economic
resources, such as safety-net health centers, have
a particular role to play in ensuring equitable
access to cancer-prevention programs. However,
given limited resources and high demand, it can
be difficult to integrate new practices into such
organizations. Initial work suggests that some
of the characteristics of an organization or community (e.g., the willingness of leaders to engage,
tension with regard to change or a perception
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that the current situation is intolerable, and the
presence of formally appointed implementation
leaders), in addition to characteristics of the intervention itself, differentiate systems that adopt
evidence-based practices from lower-performing
systems.44,45 Research is needed that incorporates
the full range of factors that influence implementation in areas that serve populations with a
high cancer burden and limited resources.46
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